The company has added a new 26,000-square-foot research site at 3624 Market St., which houses many of its 60 scientists focused on antibody research and innovation. The company also has operations in the Science Center at 3711 Market St.
“We are excited and proud to be a product of Philadelphia — created here, growing here, expanding here,” said Ben Doranz, CEO of Integral Molecular. “This new space allows us to continue to be innovative in our mission to obtain antibodies against hard to treat diseases.”
The cost of the new research site is being kept confidential.
Founded in 2001 by Doranz and Sharon Willis, the company’s vice president of sales, Integral Molecular develops biotherapeutics to treat diseases with no available cures by focusing on a group of proteins found on the surface of cells. Technology developed by Integral Molecular has been integrated into the drug discovery pipelines of more than 300 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, auto-immune disorders and viral threats such as Ebola, Zika and Dengue.
The company, spun out of the University of Pennsylvania, has received $50 million in National Institutes of Health grants and contract research funding.
Integral Molecular is hosting a grand opening event for its new research center Thursday night, where Philadelphia Mayor Jim Kenney and Curt Hess, senior vice president of the Science Center, are expected to speak.